101 related articles for article (PubMed ID: 25862896)
1. Expression of phosphorylated Akt, mTOR and MAPK in type I endometrial carcinoma: clinical significance.
Kourea HP; Nikolaou M; Tzelepi V; Adonakis G; Kardamakis D; Tsapanos V; Scopa CD; Kalofonos C; Decavalas G
Anticancer Res; 2015 Apr; 35(4):2321-31. PubMed ID: 25862896
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
4. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Sun CH; Chang YH; Pan CC
Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
[TBL] [Abstract][Full Text] [Related]
5. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.
Pelloski CE; Lin E; Zhang L; Yung WK; Colman H; Liu JL; Woo SY; Heimberger AB; Suki D; Prados M; Chang S; Barker FG; Fuller GN; Aldape KD
Clin Cancer Res; 2006 Jul; 12(13):3935-41. PubMed ID: 16818690
[TBL] [Abstract][Full Text] [Related]
6. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract][Full Text] [Related]
7. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
Takahashi Y; Kohashi K; Yamada Y; Endo M; Setsu N; Ishii T; Yamamoto H; Iwamoto Y; Oda Y
Hum Pathol; 2014 May; 45(5):984-93. PubMed ID: 24746202
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
10. Localisation of phosphorylated mTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer.
Yoshida Y; Kurokawa T; Horiuchi Y; Sawamura Y; Shinagawa A; Kotsuji F
Eur J Cancer; 2010 Dec; 46(18):3445-52. PubMed ID: 20926288
[TBL] [Abstract][Full Text] [Related]
11. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.
Ouyang DQ; Liang LZ; Ke ZF; Zheng GS; Weng DS; Yang WF; Su YX; Liao GQ
Head Neck; 2017 Jun; 39(6):1145-1154. PubMed ID: 28230926
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
[TBL] [Abstract][Full Text] [Related]
13. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
[TBL] [Abstract][Full Text] [Related]
15. The phosphatidylinositol 3' kinase-Akt-mammalian target of rapamycin pathway in smooth muscle tumors of the uterus: selected protein expression patterns and their clinicopathologic implications.
Fadare O; Renshaw I; Olson SJ; Liang SX
Int J Gynecol Pathol; 2011 May; 30(3):244-51. PubMed ID: 21464729
[TBL] [Abstract][Full Text] [Related]
16. lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR.
Du Y; Wang L; Chen S; Liu Y; Zhao Y
Mol Carcinog; 2018 Sep; 57(9):1191-1200. PubMed ID: 29745433
[TBL] [Abstract][Full Text] [Related]
17. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior.
Ferrandiz-Pulido C; Masferrer E; Toll A; Hernandez-Losa J; Mojal S; Pujol RM; Ramon y Cajal S; de Torres I; Garcia-Patos V
J Urol; 2013 Dec; 190(6):2288-95. PubMed ID: 23764082
[TBL] [Abstract][Full Text] [Related]
18. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
Ettl T; Schwarz-Furlan S; Haubner F; Müller S; Zenk J; Gosau M; Reichert TE; Zeitler K
Oral Oncol; 2012 Sep; 48(9):822-30. PubMed ID: 22445095
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
